Description of Medical ServiceAnaplastic lymphoma kinase (ALK) Fluorescence in situ hybridisation (FISH) testing identifies tumours that carry the ALK rearrangement obtained from patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), which is of non-squamous histology or histology not otherwise specified. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for brigatinib for the treatment of patients with the ALK rearrangement.
Description of Medical ConditionALK-positive locally advanced or metastatic NSCLC, which is of non-squamous histology or histology not otherwise specified.
Reason for ApplicationAmendment to MBS item
Medical Service TypeInvestigative
Previous Application Number/sNot applicable
Public Summary DocumentPublic Summary Document (PDF 329 KB)
Public Summary Document (Word 65 KB)